Biogen Takes a Major Step Forward in Lupus Treatment

In a significant development, Biogen has made a major breakthrough in its phase 3 trial of Dapirolizumab Pegol for Systemic Lupus Erythematosus. This milestone marks a crucial step towards bringing relief to millions of people worldwide who suffer from this debilitating autoimmune disease.

The company’s stock price has been on a rollercoaster ride over the past year, reaching a 52-week high of $238 in July 2024 and plummeting to a low of $110.04 in April 2025. However, as of the last close, Biogen’s stock price has stabilized at $130.65, providing a glimmer of hope for investors.

So, what does this mean for Biogen’s valuation? Let’s take a closer look at the numbers. The company’s price-to-earnings ratio stands at 13.06, indicating that investors are willing to pay $13.06 for every dollar of earnings. Meanwhile, the price-to-book ratio of 1.14 suggests that Biogen’s stock is trading at a relatively modest premium to its book value.

Here are some key statistics that provide a snapshot of Biogen’s current valuation:

• Current stock price: $130.65
• 52-week high: $238 (July 2024)
• Price-to-earnings ratio: 13.06
• Price-to-book ratio: 1.14

As Biogen continues to push the boundaries of lupus treatment, investors will be watching closely to see how this breakthrough translates into long-term growth and profitability.